Logo der Gerresheimer AG
Therapeutic Areas

Diabetes & Obesity

Trusted long-term partner for primary packaging products and drug delivery devices

As the global prevalence of obesity and diabetes increases, so too does the need for therapeutic solutions. To support this growing demand we offer primary packaging and customized delivery devices such as pen injectors that are ideally suited for GLP-1 and insulin.

Facts and figures

About 422 million people worldwide have diabetes

Gerresheimer was one of the first supplier of cartridges for insulins

Worldwide, more than 1 billion people have obesity

Gerresheimer was already a solution supplier for the first-generation GLP-1 products

Type 2 diabetes makes up about 95% of the occurrences of the disease

With over 350 million pens produced per year, Gerresheimer is one of key suppliers of pen injectors

1.5 million deaths are directly attributed to diabetes each year

Diabetes mellitus

Diabetes is a generic term for various metabolic diseases which have in common that they lead to elevated blood glucose levels because patients lack the hormone insulin and/or the insulin effect is reduced. Medically, there are different forms of diabetes, the main forms are type 1 and type 2 diabetes mellitus.

Obesity

Obesity is a medical condition, in which excess body fat has accumulated to such an extent that it may negatively affect health. People are classified as obese when their body mass index (BMI) is over 30 kg/m2.
Excess body fat underlies 64% of cases of type II diabetes in men and 77% of cases in women. Since 2013 obesity is officially classified as a disease.

In the field of diabetes, we cover the entire spectrum of diabetes products

Insulin is a well-known peptide hormone which is produced by the beta cells of the pancreatic islets of the human body. Those hormones promote the development and the maturation of cells in various organs. Insulin is required to take up glucose (sugar) in liver, muscle and fat cells to build energy stores. 
For type I diabetes mellitus patients' insulin is key to survive.

Reliable supplier of integrated drug delivery systems for GLP-1

Incretin mimetics or GLP-1 receptor agonists are a class of antidiabetic agents that were originally developed specifically for the treatment of type 2 diabetes mellitus. They mimic the effect of the body's own hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Compared to insulin treatment T2D patients can benefit from lower side effects, lower risks of hypoglycemia and increased weight loss.

Contact the expert

Want to know more about our
Diabetes & Obesity Solutions?

Talk to our expert!
 

Stefan Verheyden
Global Vice President Sales Pharma & Biopharma Solutions Injectables